Clinical trial • Phase I • Oncology
RO7502175 for Locally advanced or metastatic solid tumours
Phase I trial of RO7502175 for Locally advanced or metastatic solid tumours. 44 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Locally advanced or metastatic solid tumours
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 23-11-2023
- First CTIS Authorization Date
- 15-01-2024
Trial design
Phase I trial across 18 sites in Belgium, Netherlands, Spain and others.
- Target Sample Size
- 44
Recruitment
- Planned Sample Size
- 44
- Recruitment Window Months
- 17
Geography
- Total Number Of Sites
- 18
- Total Number Of Participants
- 44
Belgium
- Earliest CTIS Part Ii Submission Date
- 12-12-2023
- Latest Decision Or Authorization Date
- 03-04-2026
- Processing Time Days
- 843
- Number Of Sites
- 3
- Number Of Participants
- 6
Sites
- Site Name
- CHU De Liege
- Contact Person Name
- Christine Gennigens
- Contact Person Email
- christine.gennigens@chuliege.be
- Site Name
- Antwerp University Hospital
- Department Name
- Oncology
- Contact Person Name
- Hans Prenen
- Contact Person Email
- hans.prenen@uza.be
- Site Name
- Ziekenhuis Aan De Stroom
- Department Name
- Oncology
- Contact Person Name
- Tom Van den Mooter
- Contact Person Email
- tom.vandenmooter@zas.be
Netherlands
- Earliest CTIS Part Ii Submission Date
- 12-12-2023
- Latest Decision Or Authorization Date
- 14-03-2025
- Processing Time Days
- 458
- Number Of Sites
- 2
- Number Of Participants
- 4
Sites
- Site Name
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Department Name
- Medical Oncology
- Contact Person Name
- Neeltje Steeghs
- Contact Person Email
- CPM-CRU@nki.nl
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Medical Oncology
- Contact Person Name
- Elisabeth de Vries
- Contact Person Email
- e.g.e.de.vries@umcg.nl
Spain
- Earliest CTIS Part Ii Submission Date
- 12-12-2023
- Latest Decision Or Authorization Date
- 03-12-2025
- Processing Time Days
- 722
- Number Of Sites
- 8
- Number Of Participants
- 12
Sites
- Site Name
- Hospital Universitario Quironsalud Madrid
- Department Name
- Oncology
- Contact Person Name
- Valentina Boni
- Contact Person Email
- valentina.boni@quironsalud.es
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- ORG-100028548
- Contact Person Name
- Luis Paz-Ares Rodriguez
- Contact Person Email
- lpazaresr@seom.org
- Site Name
- Hospital Universitario Virgen De La Victoria
- Department Name
- Medical Oncology
- Contact Person Name
- Javier Garcia Corbacho
- Contact Person Email
- jgcorbacho@ibima.eu
- Site Name
- Institut Catala D'oncologia
- Department Name
- Medical Oncology
- Contact Person Name
- Ramón Salazar Soler
- Contact Person Email
- ramonsalazar@iconcologia.net
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology
- Contact Person Name
- Elena Garralda Cabanas
- Contact Person Email
- egarralda@vhio.net
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Oncology
- Contact Person Name
- Andres Cervantes Ruiperez
- Contact Person Email
- andres.cervantes@uv.es
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Oncology
- Contact Person Name
- Victor Moreno Garcia
- Contact Person Email
- victor.moreno@startmadrid.com
- Site Name
- Hospital Universitario 12 De Octubre (additional entry)
- Department Name
- ORG-100028548
Greece
- Earliest CTIS Part Ii Submission Date
- 09-04-2025
- Latest Decision Or Authorization Date
- 16-05-2025
- Processing Time Days
- 37
- Number Of Sites
- 3
- Number Of Participants
- 12
Sites
- Site Name
- Thoracic General Hospital Of Athens I Sotiria
- Department Name
- Oncology Unit, 3'd Department of Ιnternal Medicine and Laboratory
- Contact Person Name
- Konstantinos Syrigos
- Contact Person Email
- gpp.trials@gmail.com
- Site Name
- University General Hospital Attikon
- Department Name
- 2nd Propaedeutic Pathology Clinic
- Contact Person Name
- Amanda Psyrri
- Contact Person Email
- psyrri237@yahoo.com
- Site Name
- General Hospital Of Thessaloniki Papageorgiou
- Department Name
- Molecular Medicine Clinic
- Contact Person Name
- Sofia Baka
- Contact Person Email
- bakasofia@hotmail.com
Sweden
- Earliest CTIS Part Ii Submission Date
- 16-05-2025
- Latest Decision Or Authorization Date
- 23-10-2025
- Processing Time Days
- 160
- Number Of Sites
- 2
- Number Of Participants
- 10
Sites
- Site Name
- Karolinska University Hospital
- Department Name
- Centrum för Kliniska Cancerstudier, Fas 1-enheten
- Contact Person Name
- Luigi De Petris
- Contact Person Email
- luigi.depetris@regionstockholm.se
- Site Name
- Sahlgrenska University Hospital-Vastra Gotalandsregionen
- Department Name
- Avdelningen för Onkologi Jubileumsklinken
- Contact Person Name
- Edvard Abel
- Contact Person Email
- edvard.abel@vgregion.se
Sponsor
Primary sponsor
- Full Name
- Genentech Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- RO7502175
- Active Substance
- RO7502175
- Investigational Product Name
- Atezolizumab
- Active Substance
- Atezolizumab
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- BYON4228 for Locally advanced or metastatic solid tumours
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer